Hemic and Lymphatic Diseases: News and Research on Blood Coagulation Disorders

MeSH tree: C15.378.100

Benefits of valoctocogene roxaparvovec persist in hemophilia A

For patients with hemophilia A, factor VIII activity and bleeding reduction persist at two years after gene transfer with valoctocogene roxaparvovec, which delivers a B-domain-deleted factor VIII coding sequence with an adeno-associated ...

Researchers trial potential hemophilia treatment

A global study involving McMaster University researchers has trialed a potential new treatment that could be a game-changer for people living with hemophilia A, a life-threatening genetic blood disorder.

Hemophilia: Training the immune system to be tolerant

Hemophilia A is the most common severe form of hemophilia. It almost exclusively affects males. The disease can usually be treated well, but not for all sufferers. A study at the University of Bonn has now elucidated an important ...

page 6 from 7